These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 25666165)

  • 1. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
    Geary RS; Norris D; Yu R; Bennett CF
    Adv Drug Deliv Rev; 2015 Jun; 87():46-51. PubMed ID: 25666165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide pharmacokinetics and metabolism.
    Geary RS
    Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):381-91. PubMed ID: 19379126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oligonucleotides.
    Agrawal S; Zhang R
    Ciba Found Symp; 1997; 209():60-75; discussion 75-8. PubMed ID: 9383569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of antisense oligonucleotides.
    Agrawal S; Temsamani J; Galbraith W; Tang J
    Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
    Temsamani J; Roskey A; Chaix C; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
    Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
    J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate.
    Raoof AA; Chiu P; Ramtoola Z; Cumming IK; Teng C; Weinbach SP; Hardee GE; Levin AA; Geary RS
    J Pharm Sci; 2004 Jun; 93(6):1431-9. PubMed ID: 15124202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
    Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
    Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
    Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
    Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.